prikaz prve stranice dokumenta An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment
Pristup korisnicima matične ustanove
Znanstveni rad - Izvorni znanstveni rad
An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment
Prostaglandins, Leukotrienes and Essential Fatty Acids, 200 (2024); 102604. https://doi.org/10.1016/j.plefa.2023.102604
Nadalin, Sergej; Zatković, Lena; Peitl, Vjekoslav; Karlović, Dalibor; Vilibić, Maja; Silić, Ante; Dević Pavlić, Sanja; Buretić-Tomljanović, Alena

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Nadalin, S., Zatković, L., Peitl, V., Karlović, D., Vilibić, M., Silić, A. ... Buretić Tomljanović, A. (2024). An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids, 200.. doi: 10.1016/j.plefa.2023.102604

Nadalin, Sergej, et al. "An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment." Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 200, 2024. https://doi.org/10.1016/j.plefa.2023.102604

Nadalin, Sergej, Lena Zatković, Vjekoslav Peitl, Dalibor Karlović, Maja Vilibić, Ante Silić, Sanja Dević Pavlić i Alena Buretić Tomljanović. "An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment." Prostaglandins, Leukotrienes and Essential Fatty Acids 200 (2024). https://doi.org/10.1016/j.plefa.2023.102604

Nadalin, S., et al. (2024) 'An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment', Prostaglandins, Leukotrienes and Essential Fatty Acids, 200. doi: 10.1016/j.plefa.2023.102604

Nadalin S, Zatković L, Peitl V, Karlović D, Vilibić M, Silić A, i sur.. An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids [Internet]. 01.2024. [pristupljeno 10.05.2024.];200. doi: 10.1016/j.plefa.2023.102604

S. Nadalin, et al., "An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment", Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 200, Siječanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:091129. [Citirano: 10.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:091129
Podaci o radu
Naslov (engleski)An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment
AutorSergej Nadalin
AutorLena Zatković
AutorVjekoslav Peitl
AutorDalibor Karlović
AutorMaja Vilibić
AutorAnte Silić
AutorSanja Dević Pavlić
AutorAlena Buretić-Tomljanović
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za medicinsku biologiju i genetiku)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Psihijatrija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Genetika, genomika i proteomika čovjeka
Sažetak (engleski)
Peroxisome proliferator-activated receptor alpha (PPARα) and antipsychotic medications both influence poly unsaturated fatty acids (PUFA) homeostasis, and thus PPARα polymorphism may be linked to antipsychotic treatment response. Here we investigated whether the functional leucine 162 valine (L162V) polymorphism in PPARα influenced antipsychotic treatment in a group of psychosis patients (N = 186), as well as in a patient subgroup with risperidone, paliperidone, or combination treatment (N = 65). Antipsychotic-naïve first-episode patients and nonadherent chronic individuals were genotyped by polymerase chain reaction analysis. At base line, and after 8 weeks of treatment with various antipsychotic medications, we assessed the patients’ Positive and Negative Syndrome Scale (PANSS) scores; PANSS factors; and metabolic syndrome-related parameters, including fasting plasma lipid and glucose levels, and body mass index. In the total patient group, PPARα polymorphism did not affect PANSS psychopathology or metabolic parameters. However, in the subgroup of patients with risperidone, paliperidone, or combination treatment, PPARα polymorphism influenced changes in plasma LDL cholesterol. Specifically, compared to PPARα-L162L homozygous patients, PPARα-L162V hetero zygous individuals exhibited significantly higher increases of LDL cholesterol levels after antipsychotic treat ment. The PPARα polymorphism had a strong effect size, but a relatively weak contribution to LDL cholesterol level variations (~12.8 %).
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaProstaglandins, Leukotrienes and Essential Fatty Acids
Brojčani podacivol. 200, 102604
p-ISSN0952-3278
DOIhttps://doi.org/10.1016/j.plefa.2023.102604
URN:NBNurn:nbn:hr:184:091129
Datum objave publikacije2024-01
ProjektŠifra: uniri-biomed-18-251
Naziv (hrvatski): Genetički i biokemijski biljezi metabolizma membranskih fosfolipida i masnih kiselina kao predskazatelji odgovora na antipsihotičnu terapiju u bolesnika s psihotičnom epizodom
Naziv (engleski): Genetic and biochemical markers of the membrane phospholipid and fatty acid metabolism as predictors of treatment response to antipsychotic therapy in patients with psychotic episodes
Voditelj: Alena Buretić-Tomljanović
Pravna nadležnost: Hrvatska
Financijer: NadSve
Linija financiranja: Nema
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S095232782300073X
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-02-13 07:56:01